ADVENTRX Pharmaceuticals announces 6-month stability data for Exelbine

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site. The 6-month stability data are on track to support the submission of the New Drug Application (NDA) for Exelbine.  

"These results are what we expected and what we expect to see from the 12-month data," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Once we have the 12-month data, we will submit the Exelbine NDA, which we expect will take place in the fourth quarter of this year."


ADVENTRX Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Drug combinations may help to slow the progression of diabetic kidney disease